BioSpace News Archive

Veneto Holdings, LLC, is a private business; its shareholders are or were private shareholders of Generex Biotechnology, Inc.. Veneto writes to correct the false record Generex, and its CEO, Joe Moscato, have placed in the public domain.

Vizient, Inc. has identified 200 essential medications whose absence may threaten hospitals’ ability to provide immediate and high quality patient care, including 77 acute and chronic life-saving drugs that have no alternatives in the event of a supply disruption.

Alma, Inc., announces the North American release of Opus™, a new modern aesthetic platform featuring the company’s proprietary high-frequency unipolar radio-frequency technology, Opus Plasma™.

At the end of 2019, exocad GmbH announced the worldwide availability of the new software version DentalCAD 2.4 Plovdiv - after Matera in March 2019, the second comprehensive release of the year.

Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced that it has appointed Juergen Froehlich, MD, MBA, to its Board of Directors.

Biofourmis, a fast-growing global leader in digital therapeutics that powers personally predictive care, has named two highly experienced and skilled business leaders with deep, highly relevant backgrounds as the company’s chief operating officer (COO) and chief technology officer (CTO).

TILT Biotherapeutics (“TILT”), a privately held biopharmaceutical company based in Helsinki, Finland, today announces that they have signed a license agreement with Biotheus Inc. (“Biotheus”), a privately held Chinese company based in Zhuhai, Guangdong, China.

R1 RCM Inc. (NASDAQ:RCM), a leading provider of technology-enabled revenue cycle management (RCM) services to healthcare providers, announced its continued expansion into the physician practice market with the addition of District Medical Group, a not-for-profit integrated medical group practice with more than 650 providers, representing more than 25 specialties.

To the Detriment of the Sickle Cell Disease Community, the Draft Report Does Not Accurately Reflect or Interpret the Original Clinical Data and Related Efficacy and Safety of L-Glutamine Validated and Approved by the FDA

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has been selected by upcyte® technologies GmbH as the exclusive commercial worldwide distributor of its cell products and media, including cells derived from hepatocytes and liver sinusoidal endothelial cells (LSECs).